In its software, Lykos describes MDMA being a catalyst for that therapeutic course of action, which is why it received so much focus. That is not anticipated to become just as much of a keep-up for other psychedelics, though. “The remainder of us are studying molecules that don't require the identical diploma of therapy,” claims Kabir Nath, CEO… Read More